Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZW191 phase 1 study in advanced folate receptor alpha-expressing solid tumors
jRCT2031240343Phase 1Active, not recruiting
- Sponsor
- Zymeworks Inc.
- Start
- Oct 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 1, open-label trial of ZW191 in ovarian cancer, endometrial cancer (EC) and non-small cell lung cancer (NSCLC) (4 arms), sponsored by Zymeworks Inc. Primary endpoints: Frequency and severity of dose-limiting toxicities, Frequency and severity of adverse events and 5 more. Started Oct 2024; status: active, not recruiting.
02
Drugs
ZW191
03
Conditions
ovarian cancerendometrial cancer (EC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031240343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240343.